S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
New York goes dark, then America. (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
New York goes dark, then America. (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
New York goes dark, then America. (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Urgent alert: open this for a huge profit potential (Ad)
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
New York goes dark, then America. (Ad)
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
Free Trial
NASDAQ:XBIT

XBiotech (XBIT) Stock Price, News & Analysis

→ The #1 Crypto for 2024 (From InvestorPlace) (Ad)
Free XBIT Stock Alerts
$8.04
+0.13 (+1.64%)
(As of 04/19/2024 ET)
Compare
Today's Range
$7.51
▼
$8.34
50-Day Range
$5.78
▼
$9.89
52-Week Range
$3.05
▼
$9.96
Volume
76,231 shs
Average Volume
61,499 shs
Market Capitalization
$244.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
XBIT stock logo

About XBiotech Stock (NASDAQ:XBIT)

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBIT Stock Price History

XBIT Stock News Headlines

April 18, 2024 | americanbankingnews.com
XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $7.19
March 20, 2024 | finance.yahoo.com
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders
April 20, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
March 18, 2024 | investorplace.com
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023
March 8, 2024 | finance.yahoo.com
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
February 17, 2024 | finance.yahoo.com
XBIT Mar 2024 5.000 call
January 18, 2024 | morningstar.com
XBiotech Inc XBIT
January 8, 2024 | bizjournals.com
A top Austin biopharmaceutical company is doubling down on its Austin campus
April 20, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
January 4, 2024 | finance.yahoo.com
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
December 15, 2023 | msn.com
ARCT, EHTH and CRTO are among after hour movers
December 5, 2023 | finance.yahoo.com
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
November 14, 2023 | finanznachrichten.de
XBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
November 14, 2023 | finance.yahoo.com
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
September 26, 2023 | finance.yahoo.com
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
August 8, 2023 | finanznachrichten.de
XBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
August 8, 2023 | finance.yahoo.com
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
June 30, 2023 | thestreet.com
XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny
May 23, 2023 | finanznachrichten.de
XBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 22, 2023 | finance.yahoo.com
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 17, 2023 | finanznachrichten.de
XBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 17, 2023 | finance.yahoo.com
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
April 17, 2023 | finanznachrichten.de
XBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 17, 2023 | finance.yahoo.com
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 9, 2023 | finance.yahoo.com
XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders
February 15, 2023 | finance.yahoo.com
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable
November 11, 2022 | finance.yahoo.com
XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)
See More Headlines
Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2024
Today
4/19/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XBIT
CUSIP
N/A
CIK
1626878
Web
www.xbiotech.com
Phone
(512) 386-2900
Fax
512-386-5505
Employees
82
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,560,000.00
Net Margins
N/A
Pretax Margin
-7,401.67%
Return on Equity
-10.82%
Return on Assets
-10.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.07
Quick Ratio
33.07

Sales & Book Value

Annual Sales
$4.01 million
Price / Sales
61.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.19 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
30,450,000
Free Float
21,803,000
Market Cap
$244.82 million
Optionable
Optionable
Beta
1.45
10 Best Stocks to Own in 2024 Cover
10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

XBIT Stock Analysis - Frequently Asked Questions

How have XBIT shares performed in 2024?

XBiotech's stock was trading at $4.00 at the beginning of 2024. Since then, XBIT stock has increased by 101.0% and is now trading at $8.04.
View the best growth stocks for 2024 here.

When is XBiotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our XBIT earnings forecast.

How were XBiotech's earnings last quarter?

XBiotech Inc. (NASDAQ:XBIT) released its quarterly earnings data on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter.

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

When did XBiotech IPO?

XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XBIT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends